PRESS RELEASE

June 13, 2014

Lytix Biopharma starts subsidiary within antimicrobial coating

Lytix Biopharma has developed its antimicrobial technology further and patent protected a unique principle where effector molecules can be linked to different surfaces. This implies that many different products can be made self-sterilizing. Today, formulations of silver, copper and other heavy metals are used for this purpose. There is a clear need for more environmental friendly and custom made solutions, which is what Lytix Biopharma`s technology represent.

Antimicrobial surface treatment is a growth area within medical applications (instruments, urine catheters, needles, bandages, implant surgery etc.), within consumer applications (food packaging, clothing /sport clothing, sanitary articles etc.) and other industrial applications (air ventilation, impregnation/painting, water cleaning, heat exchange units etc.).



No coating | Coating with low-active peptide | Coating with active peptide

The pictures show green polystyrene particles, the red coating is bacterial biofilm which does not grow on the particles coated with Lytix Biopharma`s antimicrobial technology.

The Board of Lytix Biopharma has decided to establish this technology area in a subsidiary company. The reason is that the expertise, business model, and application areas are very different from drug development.

The new company is called Lytix Amicoat (antimicrobial coating).
The company is established in Tromsø where the core competency within the chemical technology is based. The Board of Lytix Biopharma has decided that Knut Eidissen (Chairman of the Board of Lytix Biopharma) becomes Chairman of the Board of Lytix Amicoat, Håvard Selbye Ebbestad (member of the Board of Lytix Biopharma) and Unni Hjelmaas (CEO of Lytix Biopharma) become members of the Board.

By spinning out this technology Lytix Biopharma realize a potential added value for our shareholders. It is important that Lytix Biopharma focus on the clinical projects which are cancer immunotherapy and treatment of topical infections says CEO Unni Hjelmaas, Lytix Biopharma.

For further information:

CEO Unni Hjelmaas
004791519651/unni.hjelmaas@lytixbiopharma.com

Chairman of the Board Knut Eidissen
004791617707/knut.eidissen@lytixbiopharma.com

Lytix Biopharma's technology is based on nature's own defense mechanism. The membranes of bacteria and cancer cells are destroyed. Our technology has the potential to meet two substantial medical challenges: treatment of infections regardless of resistance and cancer therapy that activates the patient`s own immune system. Lytix Biopharma's strategy is to develop its drug candidates to Proof of Concept, and then bring in partners for further stages of product development and commercialization. See www.lytixbiopharma.com.